Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,086
Total Claims
$2.5M
Drug Cost
1,028
Beneficiaries
$2,460
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
-37%
Cost per patient vs peers
$2,460 vs $3,933 avg
-30%
Brand preference vs peers
35.8% vs 51.2% avg
Opioid Prescribing
0.7%
Opioid Rate
74
Opioid Claims
$3,038
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,515 claims · $2.2M
Generic: 6,307 claims · $214K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 159 | $206K |
| Empagliflozin | 179 | $186K |
| Dulaglutide | 89 | $186K |
| Insulin Lispro | 119 | $136K |
| Sitagliptin Phosphate | 133 | $129K |
| Insulin Glargine,hum.Rec.Anlog | 148 | $125K |
| Insulin Detemir | 117 | $100K |
| Insulin Aspart | 110 | $93K |
| Insulin Regular, Human | 47 | $81K |
| Semaglutide | 54 | $80K |
| Lanreotide Acetate | 13 | $76K |
| Dapagliflozin Propanediol | 83 | $72K |
| Apixaban | 243 | $63K |
| Insulin Aspart | 36 | $60K |
| Insulin Degludec | 65 | $55K |
Prescribing Profile
Patient Profile
71
Avg Age
65%
Female
1.99
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About